by Heather Dolan

What does the Impact of GLP-1 medications mean for hospitality?

What does the Impact of GLP-1 medications mean for hospitality?

Currently, around 4–7% of UK adults (approximately 2.1–3.7 million people) are using GLP-1 medications such as Wegovy, Ozempic and Mounjaro for weight loss, with usage roughly doubling between 2024 and 2025 (KAM). These drugs suppress appetite, meaning users typically eat less and need to make careful food choices to meet their nutritional needs (British Nutrition Foundation).

As a result, when eating out, many are seeking venues that offer healthier options and allow customisation, while research also suggests 65% say they now choose different types of food and are willing to pay a premium for healthier options (KAM).

Venues can respond by offering smaller portions and incorporating more nutrient-dense ingredients such as beans, lean meat, fish, wholegrains, nuts, seeds, fruit and vegetables. This reflects a broader shift in the UK eating-out market, where growing health awareness extends beyond GLP-1 users, driving demand for dishes that are higher in protein and fibre and lower in sugar, without compromising on flavour (Lumina Intelligence UK Menu & Food Trends Report). The key opportunity for operators will be balancing these nutrient-dense choices with familiar favourites to reflect how consumers’ eating habits are evolving.

Latest Industry Insight

Holiday Tax confirmed

by Vicki Philpott | Business Development Controller, Travel & Leisure

We are disappointed by the Government’s confirmation in last week’s King’s Speech that it intends to proceed with a tourism...

Holiday Tax confirmed
Back to Top